<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02460432</url>
  </required_header>
  <id_info>
    <org_study_id>MIRA-003</org_study_id>
    <nct_id>NCT02460432</nct_id>
  </id_info>
  <brief_title>Comparison of Drug Eluting Stent and Covered Metal Stent in Malignant Biliary Obstruction (MIRA III)</brief_title>
  <official_title>A Prospective, Randomized, Single Blind Study to Evaluate the Effectiveness and Safety Comparing Niti-S Mira-Cover III Biliary Stent With ComVi Biliary Covered Stent in Patients With Malignant Biliary Obstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taewoong Medical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taewoong Medical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effectiveness and safety of Niti-S Mira-Cover III
      Biliary Stent with Comvi Biliary Covered Stent for the treatment of malignant biliary
      obstruction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients with malignant biliary obstruction, endoscopic placement of biliary stents offers
      similar technical success rates. Endoscopic retrograde cholangiography (ERCP)-guided stent
      placement has become the preferred approach to palliate malignant biliary obstruction. The
      major mechanisms of self-expandable metallic stent (SEMS) occlusion are tumor ingrowth, tumor
      overgrowth, and epithelial hyperplasia. These mechanisms provide the rationale for developing
      a drug-eluting stent in order to improve stent patency. Limited data exist regarding outcomes
      of paclitaxel-eluting stents in malignant biliary obstruction. This study is to prospectively
      compare the effectiveness and safety of paclitaxel-eluting covered metal stent and covered
      metal stent for the treatment of malignant biliary obstruction.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">December 26, 2016</completion_date>
  <primary_completion_date type="Actual">December 26, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative stent patency during 6months after stent placement</measure>
    <time_frame>6 month</time_frame>
    <description>Stent patency is defined as absence of stent obstruction and confirmed by computed tomography (CT) or ERCP.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stent migration</measure>
    <time_frame>6 month</time_frame>
    <description>Stent migration is defined as an obvious dislodgement from the intended and original implant position and confirmed by radiography, CT, or ERCP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary stent insertion due to recurrent biliary obstruction</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean survival</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Biliary Neoplasms</condition>
  <condition>Biliary Obstruction</condition>
  <condition>Pancreatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Paclitaxel-eluting metal Stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Niti-S Mira-Cover III Biliary Stent (TaeWoong Medical Co., Ltd. Korea)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Covered Metal Stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ComVi Biliary Covered Stent (TaeWoong Medical Co., Ltd. Korea)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Paclitaxel-eluting metal Stent</intervention_name>
    <description>Insertion of Niti-S Mira-Cover III Biliary Stent using ERCP</description>
    <arm_group_label>Paclitaxel-eluting metal Stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Covered Metal Stent</intervention_name>
    <description>Insertion of ComVi Biliary Covered Stent using ERCP</description>
    <arm_group_label>Covered Metal Stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than or equal to 19 years of age

          -  Malignant mid or distal biliary obstruction

          -  Unresectable cancer

          -  Estimated survival greater than or equal to 3 months (Karnofsky score â‰¥ 60)

          -  Patient willing to provide written informed consent and comply with follow-up
             requirements

        Exclusion Criteria:

          -  Patients who had undergone surgical biliary drainage

          -  Severe bleeding disorder (e.g. coagulopathy)

          -  Polypoid lesion or intra-abdominal abscess

          -  Female of child-bearing potential who are unable to take adequate contraceptive
             precautions, are known to be pregnant, or are currently breastfeeding an infant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong Ki Lee, Ph.D MD</last_name>
    <role>Study Chair</role>
    <affiliation>Gangnam Severance Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kyu Taek Lee, Ph.D MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sang Hyub Lee, Ph.D MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Don Haeng Lee, Ph.D MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>In Ha University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jung Sik Choi, Ph.D MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <state>Bokji-ro Busanjin-gu</state>
        <zip>633-165</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Haehak-ro Jongno-gu</state>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>In Ha University Hospital</name>
      <address>
        <city>Incheon</city>
        <state>Inhang-ro Jung-gu</state>
        <zip>400-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Irwon-Dong, Gangnam-Gu</state>
        <zip>130-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>135-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2015</study_first_submitted>
  <study_first_submitted_qc>May 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2015</study_first_posted>
  <last_update_submitted>April 7, 2017</last_update_submitted>
  <last_update_submitted_qc>April 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug-eluting Biliary stent</keyword>
  <keyword>Covered metalic stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>February 12, 2016</ipd_description>
  </patient_data>
  <pending_results>
    <submitted>July 24, 2017</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>July 25, 2017</submitted>
    <returned>December 18, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

